EnsoData enhances home sleep apnea test
By HME News Staff
Updated 2:36 PM CDT, Mon April 14, 2025
MADISON, Wis. – EnsoData is enhancing the EnsoSleep PPG, a home sleep apnea testing solution that’s cleared by the U.S. Food and Drug Administration, by integrating three new physical channels. The company says the new channels will provide additional physiological data to support sleep clinicians in diagnosing and treating sleep disorders using FDA-cleared pulse oximeters. “Adding three new channels is a major step forward for EnsoSleep PPG,” said Fred Turkington, SVP of product management, EnsoData. “The new flow, snore and actigraphy data are added on top of the existing respiratory analysis of peripheral arterial tone. These channels make raw data interpretation more intuitive for physicians by aligning PPG-based home sleep testing more closely with in-lab PSGs and legacy HSAT signals. Best of all, we accomplished this with no extra hardware for patients to manage. They need only their smartphone and a pulse oximeter." EnsoData says the FDA-cleared Drowzle Pro, rebranded as Celeste+, captures acoustic flow and snore data from the microphone of a mobile device, while the actigraphy channel displays movement data from accelerometers embedded in existing PPG-enabled devices. Celeste+ also includes the EnsoData Audio Respiratory Score (eARS), a metric that tracks the number of breathing interruptions per hour using only the built-in microphone on the patient’s smartphone. EnsoData is providing the new channels, which don’t require additional hardware, at no extra cost.
Comments